otiti
media
om
caus
respiratori
viru
andor
bacteri
infect
middl
ear
space
result
host
respons
infect
acut
otiti
media
aom
occur
frequent
consequ
viral
upper
respiratori
tract
infect
urti
lead
eustachian
tube
inflammationdysfunct
neg
middl
ear
pressur
movement
secret
contain
urticaus
viru
pathogen
bacteria
nasopharynx
middl
ear
cleft
use
comprehens
sensit
microbiolog
test
bacteria
andor
virus
detect
middl
ear
fluid
mef
aom
case
eg
bacteria
virus
togeth
bacteria
alon
viru
alon
studi
use
less
sensit
less
comprehens
microbiolog
assay
yield
less
posit
result
bacteria
much
less
posit
result
virus
epidemiolog
studi
shown
strong
relationship
viral
upper
respiratori
infect
uri
aom
chonmaitre
et
al
report
uri
episod
children
less
year
age
usa
posit
respiratori
virus
adenoviru
coronaviru
respiratori
syncyti
viru
rsv
frequent
relat
aom
children
aom
japan
respiratori
virus
detect
patient
n
rsv
influenza
viru
adenoviru
common
virus
griev
et
al
studi
rsv
pathogenesi
chinchilla
investig
viral
uri
lead
aom
nasal
rsv
challeng
viral
replic
seen
site
inocul
pharyng
orific
eustachian
tube
h
viru
could
detect
distal
part
eustachian
tube
day
rsv
adenovirus
still
among
import
virus
associ
aom
prospect
longitudin
studi
children
younger
year
usa
uri
episod
posit
respiratori
virus
rhinoviru
adenoviru
frequent
detect
uri
caus
singl
viru
rate
aom
complic
uri
highest
episod
caus
adenoviru
coronaviru
rsv
molecular
technolog
made
possibl
detect
new
respiratori
virus
relat
aom
human
metapneumovirus
hmpv
discov
decad
ago
recogn
import
pathogen
caus
lower
respiratori
tract
infect
urti
children
cohort
children
respiratori
symptom
hmpv
detect
children
infect
complic
aom
incid
hmpv
highest
children
younger
year
children
younger
year
age
hmpv
infect
complic
aom
human
bocaviru
hbov
discov
date
signific
hbov
caus
symptomat
ill
still
controversi
hbov
occur
frequent
conjunct
virus
seem
persist
long
time
respiratori
tract
asymptomat
children
hbov
detect
respiratori
specimen
alarmingli
high
rate
children
aom
beder
et
al
report
hbov
detect
rate
nasopharyng
secret
np
mef
resolut
time
aom
longer
rate
fever
higher
children
hbov
viru
also
detect
mef
young
children
otiti
media
effus
ome
role
viru
aom
ome
requir
investig
new
old
picornavirus
also
studi
associ
aom
young
children
aom
new
rhinoviru
human
rhinoviru
speci
c
hrvc
detect
almost
half
rhinovirusposit
np
mef
sampl
studi
children
aom
japan
yano
et
al
found
case
cytomegaloviru
cmv
infect
five
case
month
age
primari
cmv
infect
reactiv
document
immunoglobulin
igm
serolog
four
five
cmv
viral
nucleic
acid
mef
two
five
bacteria
cultur
mef
investig
suggest
role
cmv
aom
etiolog
similar
find
previous
report
cmv
rare
caus
viral
uri
young
children
like
contribut
viru
aom
limit
although
possibl
pathogenesi
aom
involv
complex
interact
virus
bacteria
acut
viral
infect
nasopharynx
creat
environ
promot
growth
pathogen
bacteria
alreadi
colon
nasopharynx
promot
adhes
epitheli
cell
invas
middl
ear
symptom
viral
urti
usual
last
week
viral
shed
nasopharynx
may
last
week
longer
studi
viral
persist
nasopharynx
viral
transmiss
asymptomat
infect
becom
import
understand
pathogenesi
uri
aom
viral
infect
upper
respiratori
tract
usual
induc
major
minor
damag
respiratori
mucosa
follow
promot
growth
pathogen
bacteria
nasopharynx
enhanc
bacteri
adhes
epitheli
cell
eventu
invas
middl
ear
caus
aom
ishizuka
et
al
report
rhinoviru
infect
cultur
human
airway
epitheli
cell
stimul
streptococcu
pneumonia
adhes
airway
epitheli
cell
via
increas
plateletactiv
receptor
pafr
increas
adher
pneumonia
may
one
reason
aom
pneumonia
develop
rhinoviru
infect
induc
surfac
express
pafr
receptor
pneumonia
mous
model
sendai
viru
coinfect
pneumonia
moraxella
catarrhali
increas
incid
rate
durat
aom
bacteri
load
human
studi
detect
rhinoviru
adenoviru
nasopharynx
posit
associ
presenc
haemophilu
influenza
aborigin
children
catarrhali
aborigin
nonaborigin
children
howev
adenoviru
neg
associ
pneumonia
aborigin
children
tomochika
et
al
report
japan
hospit
children
rsv
aom
rsv
nasal
inocul
chinchilla
reduc
express
antimicrobi
peptid
chinchilla
bdefensin
increas
load
h
influenza
nasopharynx
infect
airway
respiratori
viru
downregul
express
bdefensin
increas
nasopharyng
colon
h
influenza
promot
develop
aom
gold
standard
determin
etiolog
bacteri
om
cultur
mef
order
determin
om
bacteriolog
cultur
mef
recov
tympanocentesi
drainag
tympanostomi
tube
spontan
otorrhea
determin
import
track
chang
distribut
pathogen
caus
om
bacteria
found
case
aom
without
otorrhea
pneumonia
nontyp
h
influenza
catarrhali
lead
caus
pathogen
respons
aom
frequent
colon
nasopharynx
streptococcu
pyogen
group
streptococci
account
less
aom
case
proport
aom
case
pathogen
bacteria
isol
mef
vari
depend
bacteriolog
techniqu
transport
issu
stringenc
aom
definit
seri
report
usa
europ
mean
percentag
case
bacteri
pathogen
isol
mef
respect
larg
seri
univers
pittsburgh
otiti
media
studi
group
report
bacteri
pathogen
mef
case
aom
studi
appli
stringent
otoscop
criteria
andor
use
bedsid
specimen
plate
solid
agar
addit
liquid
transport
media
report
rate
recoveri
pathogen
bacteria
middl
ear
exud
rang
use
appropri
stringent
diagnost
criteria
care
specimen
handl
sensit
microbiolog
techniqu
vast
major
case
aom
involv
pathogen
bacteria
either
alon
concert
viral
pathogen
clinic
bacteriolog
dramat
chang
introduct
pneumococc
conjug
vaccin
pcv
commonli
identifi
pathogen
pneumonia
prior
adopt
pneumococc
conjug
vaccin
isol
approxim
one
third
half
case
block
et
al
studi
chang
microbiolog
communitywid
vaccin
compar
cohort
vs
proport
pneumonia
significantli
decreas
nontyp
h
influenza
significantli
increas
gramneg
bacteria
betalactamaseproduc
organ
account
two
third
one
half
aom
isol
respect
term
serotyp
chang
pneumonia
vaccin
efficaci
vaccineserotyp
pneumococc
om
later
report
data
year
introduct
usa
show
strain
pneumonia
virtual
disappear
mef
children
aom
vaccin
howev
frequenc
isol
serotyp
pneumonia
mef
overal
increas
made
isol
pneumonia
h
influenza
children
aom
nearli
equal
summari
licens
modest
benefici
effect
healthi
infant
low
baselin
risk
aom
administ
highrisk
infant
earli
infanc
older
children
histori
aom
appear
benefit
prevent
episod
serotyp
major
caus
replac
diseas
follow
introduct
past
decad
serotyp
emerg
major
caus
acut
om
recurr
om
sever
mastoid
increas
often
attribut
introduct
howev
dagan
et
al
describ
emerg
serotyp
caus
om
prior
introduct
israel
analysi
antibiot
administr
pattern
suggest
antibiot
use
may
contribut
emerg
certain
lineag
pneumonia
pneumococc
vaccin
serotyp
conjug
diphtheria
protein
licens
util
protein
carrier
vaccin
releas
unit
state
fda
basi
immunogen
safeti
studi
safeti
evalu
mean
control
studi
involv
thousand
healthi
children
still
earli
evalu
true
benefit
pvc
numer
trial
develop
recommend
children
month
age
year
risk
factor
sever
pneumococc
diseas
vaccin
appli
dose
month
age
current
sever
rct
differ
newli
licens
multival
pcv
administ
earli
infanc
ongo
establish
effect
aom
result
studi
may
provid
better
understand
role
newli
licens
multival
pcv
prevent
aom
studi
tympanocentesi
four
respiratori
tract
ill
season
privat
practic
percentag
pneumonia
initi
decreas
rel
h
influenza
data
nasopharyng
colon
children
aom
shown
continu
presenc
pneumonia
colon
revai
et
al
show
differ
pneumonia
colon
rate
among
children
aom
unimmun
underimmun
fulli
immun
studi
viral
urti
includ
mostli
children
month
year
age
pneumonia
detect
nasopharyng
swab
h
influenza
detect
catarrhali
detect
data
show
nasopharyng
colon
children
vaccin
increasingli
caus
pneumonia
serotyp
contain
vaccin
use
recent
licens
pneumococc
conjug
vaccin
pattern
nasopharyng
colon
infect
common
aom
bacteri
pathogen
continu
evolv
investig
attempt
predict
type
aom
pathogen
bacteria
basi
clinic
sever
result
promis
pyogen
shown
occur
commonli
older
children
caus
greater
degre
inflamm
middl
ear
tympan
membran
tm
greater
frequenc
spontan
ruptur
tm
frequent
progress
acut
mastoid
compar
bacteri
pathogen
clinic
find
case
pneumonia
nontyp
h
influenza
studi
suggest
sign
symptom
aom
caus
pneumonia
may
sever
fever
sever
earach
bulg
tm
caus
pathogen
find
refut
result
studi
found
aom
caus
nontyp
h
influenza
associ
bilater
aom
sever
inflamm
tm
leibovitz
et
al
conclud
studi
children
aom
caus
h
influenza
n
pneumonia
n
mix
h
influenza
pneumonia
n
clinicalotolog
score
could
discrimin
among
variou
bacteri
etiolog
aom
howev
significantli
differ
clinicalotolog
score
bacteri
cultureneg
cultureposit
case
studi
middl
ear
exud
case
bullou
myring
shown
bacteriaposit
rate
primarili
pneumonia
contrast
previou
belief
mycoplasma
sp
rare
caus
agent
condit
accur
predict
bacteri
caus
aom
basi
clinic
present
without
bacteri
cultur
middl
ear
exud
possibl
specif
etiolog
may
predict
situat
publish
evid
suggest
aom
associ
conjunct
otitisconjunct
syndrom
like
caus
nontyp
h
influenza
bacteria
catarrhali
deriv
upper
respiratori
tract
high
rate
spontan
clinic
resolut
occur
children
aom
attribut
catarrhali
aom
attribut
catarrhali
rare
progress
acut
mastoid
intracrani
infect
substanti
geograph
variabl
observ
proport
om
caus
catarrhali
exampl
rate
mcatarrhali
israel
low
wherea
finland
microorgan
common
bacteri
caus
recurr
om
children
tympanostomi
tube
distribut
pathogen
chang
widespread
use
pcv
rel
proport
om
due
catarrhali
increas
studi
murin
model
nasal
colon
aom
studi
relationship
among
variou
combin
bacteri
om
pathogen
pneumonia
h
influenza
catarrhali
sendai
viru
murin
equival
human
parainfluenza
viru
report
krishnamurthi
et
al
expect
viral
infect
significantli
increas
incid
acut
om
coinfect
pneumonia
catarrhali
increas
incid
durat
pneumococc
om
compar
pneumonia
alon
pneumonia
h
influenza
togeth
host
competit
may
also
affect
select
virul
characterist
pneumonia
combin
theoret
model
vivo
nasopharyng
colon
experi
use
demonstr
competit
h
influenza
may
select
virul
strain
pneumonia
taken
whole
studi
indic
specif
combin
colon
bacteria
respiratori
virus
alter
incid
durat
om
pneumococci
sever
method
compet
cocolon
coinfect
speci
recurr
natur
acut
otiti
media
continu
burdensom
children
famili
especi
suffer
frequent
recurr
disadvantag
popul
diseas
progress
chronic
suppur
otiti
media
associ
impact
hear
loss
educ
potenti
reduc
burden
vaccineserotyp
diseas
well
shift
pneumococc
serotyp
carri
nasopharynx
toward
lower
diseasecaus
potenti
antibiot
resist
remain
challeng
success
therapi
ceftriaxoneresist
pneumococci
present
commun
increas
emerg
blactamaseneg
amoxicillinresist
nthi
identifi
global
nextgener
introduc
earli
data
suggest
efficaci
invas
pneumococc
diseas
carriag
multidrug
resist
isol
associ
treatment
failur
aom
increas
number
case
pneumococc
mastoid
promis
data
pneumococc
polysaccharid
conjug
vaccin
protein
carrier
publish
addit
confirm
efficaci
nthi
otiti
media
licens
formul
phidcv
conjug
pend
data
futur
studi
nthi
specif
number
candid
protein
antigen
progress
human
trial
sinc
remain
demonstr
multipl
candid
demonstr
necessari
requir
candid
vaccin
antigen
conserv
among
isol
surfac
exposur
immunogen
anim
protect
anim
model
diseas
specif
experiment
otiti
media
research
role
antigen
pathogenesi
diseas
elicit
respons
youngest
infant
like
product
permit
antigen
move
clinic
trial
select
antibiot
treat
aom
base
suspect
type
bacteria
antibiot
suscept
pattern
although
clinic
pharmacolog
clinic
microbiolog
result
predict
complianc
drug
also
taken
account
earli
studi
aom
patient
show
children
pneumonia
h
influenza
cultur
initi
tympanocentesi
treat
antibiot
clear
bacteria
time
second
tympanocentesi
day
later
approxim
children
infect
catarrhali
experienc
bacteriolog
cure
even
treatment
amoxicillin
antibiot
suscept
antibiot
suscept
major
aom
bacteri
pathogen
continu
chang
data
middl
ear
pathogen
becom
scanti
tympanocentesi
gener
perform
studi
children
uncompl
aom
avail
data
come
case
persist
recurr
aom
current
us
data
number
center
indic
approxim
isol
pneumonia
age
group
suscept
regular
mgkgday
highdos
mgkgday
divid
twice
daili
amoxicillin
respect
pediatr
isol
smaller
number
includ
mostli
ear
isol
collect
recurr
persist
aom
case
high
percentag
multidrugresist
pneumonia
frequent
nonvaccin
serotyp
recent
increas
frequenc
import
definit
resist
minimum
inhibitori
concentr
mic
breakpoint
set
clinic
laboratori
standard
institut
clsi
clsi
establish
new
approach
penicillin
breakpoint
approach
need
guid
appropri
treatment
take
account
whether
penicillin
given
oral
parenter
whether
patient
mening
revis
penicillin
breakpoint
infect
mening
current
studi
aom
use
new
oral
penicillin
breakpoint
defin
isol
penicillin
mic
penicillin
nonsuscept
pneumonia
pnsp
use
mic
defin
penicillinintermedi
resist
pneumonia
pisp
defin
penicillinresist
pneumonia
prsp
highdos
amoxicillin
yield
mef
level
exceed
mic
pneumonia
serotyp
intermedi
penicillin
mic
mani
highli
resist
serotyp
penicillin
mic
longer
period
dose
interv
shown
improv
bacteriolog
clinic
efficaci
compar
regular
dose
hoberman
et
al
report
superior
efficaci
highdos
amoxicillinclavulan
erad
pneumonia
middl
ear
day
therapi
compar
azithromycin
antibiot
suscept
pattern
pneumonia
expect
continu
evolv
use
conjug
vaccin
contain
serotyp
pneumonia
widespread
use
could
potenti
reduc
diseas
caus
multidrugresist
pneumococc
serotyp
diminish
need
use
higher
dose
amoxicillin
amoxicillinclavulan
aom
h
influenza
isol
produc
enzym
caus
isol
becom
resist
penicillin
current
data
differ
studi
nonaom
sourc
geograph
locat
may
compar
show
h
influenza
isol
suscept
regular
highdos
amoxicillin
data
repres
signific
decreas
h
influenza
compar
data
report
aom
guidelin
nationwid
data
suggest
catarrhali
deriv
upper
respiratori
tract
remain
suscept
amoxicillinclavulan
howev
high
rate
spontan
clinic
resolut
occur
children
aom
attribut
catarrhali
treat
amoxicillin
reduc
concern
firstlin
coverag
microorgan
aom
attribut
catarrhali
rare
progress
acut
mastoid
intracrani
infect
highdos
amoxicillin
recommend
firstlin
treatment
patient
although
number
medic
clinic
effect
justif
use
amoxicillin
relat
effect
common
aom
bacteri
pathogen
well
safeti
low
cost
accept
tast
narrow
microbiolog
spectrum
children
taken
amoxicillin
previou
day
concurr
conjunct
coverag
h
influenza
catarrhali
desir
therapi
initi
highdos
amoxicillin
clavulan
mgkgday
amoxicillin
mgkgday
clavulan
ratio
amoxicillin
clavulan
given
two
divid
dose
less
like
caus
diarrhea
amoxicillinclavulan
prepar
altern
initi
antibiot
includ
cefdinir
mgkg
per
day
one
two
dose
cefuroxim
mgkg
per
day
two
divid
dose
cefpodoxim
mgkg
per
day
two
divid
dose
ceftriaxon
mgkg
administ
intramuscularli
import
note
altern
antibiot
vari
efficaci
aom
pathogen
exampl
recent
us
data
vitro
suscept
pneumonia
cefdinir
cefuroxim
compar
amoxicillin
efficaci
vitro
efficaci
cefdinir
cefuroxim
h
influenza
approxim
compar
efficaci
amoxicillin
nearli
efficaci
amoxicillinclavulan
multicent
doubl
tympanocentesi
openlabel
studi
cefdinir
recurr
aom
attribut
h
influenza
show
erad
organ
patient
penicillinallerg
children
recent
data
suggest
crossreact
among
penicillin
cephalosporin
lower
histor
report
previous
cite
rate
crosssensit
cephalosporin
among
penicillinallerg
patient
approxim
like
overestim
rate
base
data
collect
review
studi
analyz
pool
data
studi
includ
patient
report
histori
penicillin
allergi
penicillinallerg
histori
conclud
mani
patient
present
histori
penicillin
allergi
immunolog
reaction
penicillin
chemic
structur
cephalosporin
determin
risk
crossreact
specif
agent
degre
crossreact
higher
penicillin
firstgener
cephalosporin
neglig
secondand
thirdgener
cephalosporin
differ
chemic
structur
cefdinir
cefuroxim
cefpodoxim
ceftriaxon
highli
unlik
associ
crossreact
penicillin
despit
joint
task
forc
practic
paramet
american
academi
allergi
asthma
immunolog
american
colleg
allergi
asthma
immunolog
joint
council
allergi
asthma
immunolog
state
cephalosporin
treatment
patient
histori
penicillin
allergi
select
sever
reaction
histori
show
reaction
rate
recommend
cephalosporin
case
without
sever
andor
recent
penicillinallergi
reaction
histori
skin
test
avail
macrolid
erythromycin
azithromycin
limit
efficaci
h
influenza
pneumonia
clindamycin
lack
efficaci
h
influenza
clindamycin
alon
mgkg
per
day
three
divid
dose
may
use
suspect
prsp
howev
drug
like
effect
multidrugresist
serotyp
patient
persist
vomit
otherwis
toler
oral
medic
even
tast
mask
ceftriaxon
mg
kg
administ
intramuscularli
one
two
site
anterior
thigh
intraven
demonstr
effect
initi
repeat
antibiot
treatment
aom
although
singl
inject
ceftriaxon
approv
us
food
drug
administr
fda
treatment
aom
result
doubl
tympanocentesi
studi
day
singledos
ceftriaxon
leibovitz
et
al
suggest
one
ceftriaxon
dose
may
requir
prevent
recurr
middl
ear
infect
within
day
initi
dose
antibiot
prescrib
aom
clinic
improv
note
within
h
h
diagnosi
aom
child
symptom
may
worsen
slightli
next
h
patient
symptom
begin
improv
initi
febril
temperatur
declin
within
h
irrit
fussi
lessen
disappear
sleep
drink
pattern
normal
patient
improv
h
anoth
diseas
concomit
viral
infect
may
present
caus
bacteria
may
resist
chosen
therapi
children
aom
persist
symptom
h
initi
antibacteri
treatment
may
combin
bacteri
viral
infect
would
explain
persist
ongo
symptom
despit
appropri
antibiot
therapi
literatur
conflict
correl
clinic
bacteriolog
outcom
studi
report
good
correl
rang
suggest
continu
presenc
bacteria
middl
ear
high
proport
case
persist
symptom
other
report
mef
children
aom
symptom
persist
steril
case
chang
antibiot
may
requir
children
mild
persist
symptom
children
persist
sever
symptom
aom
unimprov
otolog
find
initi
treatment
clinician
may
consid
chang
antibiot
child
initi
treat
amoxicillin
fail
improv
amoxicillinclavulan
use
patient
given
amoxicillinclavulan
oral
thirdgener
cephalosporin
may
receiv
intramuscular
ceftriaxon
mgkg
treatment
aom
unrespons
initi
antibiot
cours
ceftriaxon
shown
better
regimen
although
trimethoprimsulfamethoxazol
erythromycinsulfisoxazol
use
therapi
patient
aom
pneumococc
surveil
studi
indic
resist
two
combin
agent
substanti
therefor
patient
fail
improv
receiv
amoxicillin
neither
trimethoprimsulfamethoxazol
erythromycinsulfisoxazol
appropri
therapi
tympanocentesi
cultur
mef
consid
bacteriolog
diagnosi
suscept
test
seri
antibiot
drug
fail
improv
clinic
condit
tympanocentesi
avail
cours
clindamycin
may
use
without
antibiot
cover
nontyp
h
influenza
catarrhali
cefdinir
cefixim
cefuroxim
pneumonia
serotyp
usual
multidrugresist
may
respons
clindamycin
newer
antibiot
approv
fda
treatment
aom
levofloxacin
linezolid
may
indic
levofloxacin
quinolon
antibiot
approv
fda
use
children
linezolid
effect
resist
gramposit
bacteria
approv
fda
aom
treatment
expens
children
repeat
treatment
failur
everi
effort
made
bacteriolog
diagnosi
tympanocentesi
gram
stain
cultur
antibiot
suscept
test
organ
present
clinician
may
consid
consult
pediatr
medic
subspecialist
otolaryngologist
possibl
tympanocentesi
drainag
cultur
infecti
diseas
expert
use
unconvent
drug
levofloxacin
linezolid
tympanocentesi
avail
possibl
way
obtain
inform
middl
ear
pathogen
antimicrobi
suscept
obtain
nasopharyng
specimen
bacteri
cultur
almost
middl
ear
pathogen
deriv
pathogen
colon
nasopharynx
nasopharyng
pathogen
enter
middl
ear
caus
aom
posit
predict
valu
nasopharyng
cultur
aom
likelihood
bacteria
cultur
nasopharynx
middl
ear
pathogen
rang
pneumonia
nontyp
h
influenza
catarrhali
neg
predict
valu
likelihood
bacteria
found
nasopharynx
aom
pathogen
rang
three
bacteria
therefor
nasopharyng
cultur
neg
specif
bacteria
organ
like
aom
pathogen
neg
cultur
pneumonia
exampl
help
elimin
concern
multidrugresist
bacteria
need
unconvent
therapi
levofloxacin
linezolid
hand
pneumonia
cultur
nasopharynx
antimicrobi
suscept
pattern
help
guid
treatment
optim
durat
therapi
patient
aom
uncertain
usual
cours
therapi
deriv
durat
treatment
streptococc
pharyngotonsil
sever
studi
favor
standard
therapi
shorter
cours
children
younger
year
thu
children
younger
year
children
sever
symptom
standard
cours
recommend
cours
oral
antibiot
appear
equal
effect
children
year
age
mild
moder
aom
children
year
older
mild
moder
symptom
cours
adequ
treatment
impact
aom
child
health
far
exce
discomfort
suffer
associ
individu
episod
diseas
aom
among
largest
driver
antibiot
use
children
provid
support
prevent
diseas
import
strategi
reduc
antibiot
prescrib
subsequ
emerg
resist
aom
treatment
complic
signific
econom
cost
societi
